Abstract
Background: Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs.
Methods: Information on demography, co-morbidities, clinical data regarding IBD, symptoms suggestive of the SARS-CoV-2 infection, close contacts with SARS-CoV-2 positive patients, hospitalization, and therapies administered for COVID-19 was collected for all patients who were being treated with biologic drugs. All patients underwent SARS-CoV-2 antibody testing.
Results: Two hundred and fifty-nine patients (27 children) with a mean age of 42.2 ± 16.7 years (range 9 – 88) and a mean duration of disease of 13.4 ± 10 years (range 0.2 – 49) were enrolled. One hundred four patients (40.2%) had ulcerative colitis, and 155 (59.8%) had Crohn’s disease. About the therapy: 62 patients were receiving infliximab, 89 adalimumab, 20 golimumab, 57 vedolizumab, 27 ustekinumab, 1 thalidomide, and 3 an experimental compound. The mean Charlson Comorbidity Index was 2. Thirty-two patients (12.3%) reported respiratory symptoms, and 2 of them were hospitalized (0.77%). Two patients resulted positive for IgG against SARS-CoV-2 (0.77%).
Conclusions: In patients with IBD, treatment with biologic drug does not represent a risk factor for the SARS-CoV-2 infection.
Keywords: Biologic therapy; IBD; SARS-CoV-2.
【저자키워드】 SARS-CoV-2, IBD, Biologic therapy, 【초록키워드】 COVID-19, Treatment, SARS-CoV-2, IgG, therapy, Hospitalized, Hospitalization, children, Infection, drugs, risk, Symptom, risk factor, viral infections, Inflammatory bowel disease, Prevalence, serum, SARS-CoV-2 antibody, Patient, age, disease, co-morbidities, biologic, SARS-CoV-2 antibody testing, ulcerative colitis, close contact, respiratory symptoms, Clinical data, Charlson Comorbidity Index, positive, SARS-CoV-2 positive patients, Administered, enrolled, reported, investigated, receiving, was collected, treated, Two patient, the SARS-CoV-2, 【제목키워드】 drug, Inflammatory bowel disease, Prevalence, serum, SARS-CoV-2 antibody, COVID-19 outbreak, Impact, Patient, biologic, treated,